chartexchange

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

GlobeNewswire Inc. | Nov 7, 2026 10:01 AM EST

November 7, 2026, 10:00 AM ET

Read original article